Children ' s Cancer Group lymphoblastic leukemia : a combined analysis of prognostic markers Risk-and response-based classification of childhood B-precursor acute
暂无分享,去创建一个
Stephen P. Hunger | Jeffrey E. Rubnitz | Jonathan J. Shuster | Andrew J. Carroll | Nyla A. Heerema | William L. Carroll | Harland N. Sather | M. Loh | J. Shuster | N. Heerema | H. Sather | S. Hunger | M. Borowitz | M. Devidas | A. Carroll | N. Winick | J. Rubnitz | P. Gaynon | W. Carroll | E. Raetz | B. Camitta | K. Schultz | Meenakshi Devidas | D. Jeanette Pullen | Michael J. Borowitz | Mignon L. Loh | Kirk R. Schultz | D. Pullen | Elizabeth A. Raetz | Naomi J. Winick | Paul S. Gaynon | Bruce M. Camitta | M. Loh
[1] L. Frankel,et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[3] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[4] N. Heerema,et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Haber,et al. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Pui,et al. The eighth international childhood acute lymphoblastic leukemia workshop (‘Ponte di Legno meeting’) report: Vienna, Austria, April 27–28, 2005 , 2006, Leukemia.
[7] J. Downing,et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.
[8] J. Neglia,et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.
[9] C. Pui,et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Richard Aplenc,et al. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia , 2004, British journal of haematology.
[11] J. Shuster,et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994 , 2000, Leukemia.
[12] H. Sather,et al. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D C Ward,et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[14] N. Heerema,et al. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group , 2004, Leukemia.
[15] W. Bleyer,et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 , 2000, Leukemia.
[16] A. Look,et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. , 1992, Blood.
[17] B. Camitta,et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] N. Winick,et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Pui,et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements , 2003, Leukemia.
[20] G. M. Taylor,et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. J,et al. Rearrangement of the MLL Gene Confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia , Regardless of Presenting Age , 2002 .
[22] W. Carroll,et al. Individualized therapy for childhood acute lymphoblastic leukemia. , 2005, Personalized medicine.
[23] M. Schrappe,et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study , 2005, The Lancet.
[24] N. Heerema,et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Baruchel,et al. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE) , 2000, British Journal of Cancer.
[26] H. Sather,et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] N. Heerema,et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.
[28] M. Schrappe. Evolution of BFM trials for childhood ALL. , 2004, Annals of hematology.
[29] S. Hunger,et al. Childhood leukemia--new advances and challenges. , 2004, The New England journal of medicine.
[30] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[31] C. Pui,et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.
[32] F. Behm,et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. , 1990, Blood.
[33] D. Le Paslier,et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. , 1995, Blood.
[34] H. Sather,et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.
[35] M. Bleakley,et al. Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor , 2002, Bone Marrow Transplantation.
[36] N. Winick,et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial , 2001, Leukemia.
[37] N. Heerema,et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] P S Gaynon,et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Schrappe,et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. , 2005, JAMA.
[40] G. Leverger,et al. Francaise d ' Oncologie Pediatrique LMB 89 protocol : highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L 3 leukemia , 2001 .